Clinical trials: Schizophrenia Spectrum Disorders
Schizophrenia
Intramuscular Injections of Paliperidone Palmitate in the Arm or Buttock of Subjects With Schizophrenia
The purpose of the study is to compare the pharmacokinetic parameters (blood concentrations) of i.m. paliperidone palmitate after administration in 2 different injection sites (deltoid or gluteal).
- Trial name
- NCT00073320
- Testing
- Paliperidone Palmitate
- Volunteers
- 88 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia
The primary objective of the study is to evaluate whether armodafinil treatment is more effective than placebo as adjunctive therapy to antipsychotic medication in alleviating the negative symptoms of schizophrenia
- Trial name
- NCT00772005
- Testing
- armodafinil
- Where
- 39 sites in United States
- Volunteers
- 287 people
- Sponsor
- Cephalon
Schizophrenia
A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia.
A clinical trial study to determine the effect of an investigational drug (SEP-363856) has on the way that the drug Metformin travels through the body in people with schizophrenia.
- Trial name
- NCT04865835
- Testing
- SEP-363856, metformin
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizophreniform Disorder
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
The purpose of this study is to evaluate the efficacy and safety of long acting injectable microspheres of risperidone in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- NCT01855074
- Testing
- Risperidone
- Volunteers
- 80 people
- Sponsor
- Janssen-Cilag Ltd.
Schizophrenia
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
- Trial name
- NCT07114874
- Testing
- NBI-1117568
- Where
- 61 sites in United States, Bulgaria and 3 more
- Volunteers
- 600 people
- Sponsor
- Neurocrine Biosciences
Schizoaffective Disorder, Schizophrenia
A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.
The purpose of this study is to compare three strategies for switching patients with schizophrenia or schizoaffective disorder to the atypical antipsychotic, risperdone, after they have been unsuccessfully treated with another…
- Trial name
- NCT00378183
- Testing
- risperidone
- Volunteers
- 120 people
- Sponsor
- Janssen, LP
Schizophrenia
A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia
Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa
- Trial name
- NCT00089869
- Testing
- olanzapine, atomoxetine
- Where
- 20 sites in United States
- Sponsor
- Eli Lilly and Company
Schizophrenia
Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia
The purpose of this study is to evaluate the safety and tolerability of Lu AF11167 in patients with schizophrenia following various repeated dosing regimens of Lu AF11167 (alone or as added treatment to risperidone).
- Trial name
- NCT02202213
- Testing
- Lu AF11167
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia
This study assess pharmacokinetics and safety of multi-administration of Aripiprazole IM Depot formulation at doses of 400mg in patients with schizophrenia.
- Trial name
- NCT03285503
- Testing
- Aripiprazole IM Depot
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Otsuka Beijing Research Institute
Schizophrenia
A Study of ANAVEX3-71 in Adults With Schizophrenia
A study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and electrophysiology of ANAVEX3-71 in patients with Schizophrenia.
- Trial name
- SZ-001 (NCT06245213)
- Testing
- ANAVEX3-71 oral capsules
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Anavex Life Sciences Corp.
Schizophrenia, Affective Symptoms
Atypical Antipsychotics in the Treatment of Affective Symptoms of Schizophrenia in Hungary
This is a noninterventional observational study lead amongst psychiatrists, to assess the the overall status of schizophrenic outpatients with affective symptoms treated with atypical antipsychotics.
- Trial name
- AFFECT (NCT01534936)
- Where
- 53 sites in Hungary
- Volunteers
- 2,153 people
- Sponsor
- AstraZeneca
Schizophrenia
Bifeprunox Extension to Extension Study in Patients With Schizophrenia
The purpose of this study is to provide access to bifeprunox for patients, who have completed previous studies with bifeprunox, and require continued treatment with bifeprunox, other treatment not being adequate.
- Trial name
- NCT00861497
- Testing
- Bifeprunox
- Where
- Italy
- Volunteers
- 11 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder, Psychotic Disorders
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00128479
- Testing
- mifepristone, mifepristone 600 mg, mifepristone 1200 mg
- Where
- 44 sites in United States
- Volunteers
- 443 people
- Sponsor
- Corcept Therapeutics
Chronic Schizophrenia, Schizoaffective Disorder
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or…
- Trial name
- NCT01450514
- Testing
- Pipamperone
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- PharmaNeuroBoost N.V.
Schizophrenia, Psychotic Disorders
Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection
The purpose of this study is to assess the usefulness of the Risperdal® Consta® Treatment Guidebook in helping the doctor switch the adult patient from taking risperidone tablets daily by mouth to taking long-acting risperidone…
- Trial name
- NCT00236548
- Testing
- risperidone
- Volunteers
- 1 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Negative Symptoms in Schizophrenia
An Extension Study of a Second Course of a Digital Therapeutic for the Treatment of Experiential Negative Symptoms of Schizophrenia
The purpose of the proposed an open label extension (OLE) study is to evaluate the maintained efficacy and safety of a second consecutive course of Click Therapeutics Study App as an adjunct treatment to standard of care (SOC) in…
- Trial name
- NCT06067984
- Testing
- Study App
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Click Therapeutics, Inc.
Schizophrenia
A Study of Lurasidone HCl in Subjects With Schizophrenia
The study evaluates the effectiveness and safety of Lurasidone in subjects with schizophrenia over a period of 6 weeks.
- Trial name
- NCT03393026
- Testing
- Lurasidone
- Where
- 2 sites in Taiwan
- Volunteers
- 54 people
- Sponsor
- Standard Chem. & Pharm. Co., Ltd.
Schizophrenia
A Repeat Dose Positron Emission Tomography Study With GSK1144814
This study described in the present protocol consists of two parts. Part A is a multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of ascending doses of GSK1144814.
- Trial name
- NK1 NK3 PET (NCT01209039)
- Testing
- GSK1144814
- Where
- 2 sites in United Kingdom
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Schizophrenia
Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia
The primary objectives of this study are to evaluate the efficacy and safety of 3 fixed doses of paliperidone palmitate administered i.m. after an initial loading dose of 150 mg eq.
- Trial name
- NCT00590577
- Testing
- Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Paliperidone palmitate 100 mg eq.
- Where
- 66 sites in United States, Malaysia and 6 more
- Volunteers
- 652 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia and Predominant Negative Symptoms
Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms
To explore the efficacy of SPD489, as adjunctive therapy to a stable dose of atypical antipsychotic medication, on negative symptoms in adult subjects with clinically stable schizophrenia and predominant negative symptoms, as…
- Trial name
- NCT00922272
- Testing
- SPD489 (lisdexamfetamine dimesylate)
- Where
- 27 sites in United States
- Volunteers
- 92 people
- Sponsor
- Shire